Scilex Holding (SCLX) Preferred Stock Liabilities (2021 - 2022)
Scilex Holding (SCLX) posted quarterly Preferred Stock Liabilities of $101.3 million for Q3 2022, down 27.33% year-over-year from $139.4 million in Q3 2021, and up 1.1% quarter-over-quarter from $100.2 million in Q2 2022.
Scilex Holding (SCLX) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
Scilex Holding's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $101.3 million for Q3 2022.
- In Q3 2022, Preferred Stock Liabilities fell 27.33% year-over-year to $101.3 million; the TTM figure through Sep 2022 stood at $101.3 million (down 27.33% YoY), while the FY2021 annual figure was $139.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2022 stood at $101.3 million, up from $100.2 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $140.4 million in Q1 2022, with the low at $13.2 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 100.19 Mn |
| Mar 31, 2022 | 140.42 Mn |
| Dec 31, 2021 | 139.38 Mn |
| Sep 30, 2021 | 139.38 Mn |
| Jun 30, 2021 | 13.39 Mn |
| Mar 31, 2021 | 13.15 Mn |